Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SAB BiotherapeuticsSABS +0.58%32 EV-to-EBITDA is 56.40 as of Jul. 29, 2026. GuruFocus rates SABS with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 407 Biotechnology companies, SAB Biotherapeutics ranks worse than 86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SAB Biotherapeutics's enterprise value is $163.12 Mil.
SAB Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2.89 Mil. Therefore, SAB Biotherapeutics's EV-to-EBITDA for today is 56.40.
The historical rank and industry rank for SAB Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
SABS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 56.4
Current: 56.4
During the past 7 years, the highest EV-to-EBITDA of SAB Biotherapeutics was 56.40. The lowest was 0.00. And the median was 0.00.
SABS's EV-to-EBITDA is ranked worse than 86% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs SABS: 56.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
SAB Biotherapeutics (NAS:SABS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SAB Biotherapeutics's PE Ratio (TTM) for today is calculated as:
SAB Biotherapeutics's share price for today is $3.457.
SAB Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.306.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SAB Biotherapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SAB Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's EV-to-EBITDA falls into.
SAB Biotherapeutics's current Enterprise Value is $163.12 Mil.
SAB Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics (SABS) has a EV-to-EBITDA of 56.40 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SAB Biotherapeutics. According to the industry distribution chart, SAB Biotherapeutics ranks #350 out of 407 companies in the Biotechnology industry, placing it in the top 86%.
Is SAB Biotherapeutics' EV-to-EBITDA too high?
SAB Biotherapeutics' current EV-to-EBITDA is 56.40. The Biotechnology industry median EV-to-EBITDA is 11.70. SAB Biotherapeutics' value of 56.40 is 382.1% above this industry median. Based on the distribution chart, SAB Biotherapeutics ranks #350 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' EV-to-EBITDA compare to SLGL and BCYC?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #350 out of 407 companies for EV-to-EBITDA. This places SAB Biotherapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 11.70. SAB Biotherapeutics' value of 56.40 is 382.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SAB Biotherapeutics's current EV-to-EBITDA of 56.40 is 382.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SAB Biotherapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SAB Biotherapeutics's current EV-to-EBITDA is 56.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current EV-to-EBITDA of 56.40. The current EV-to-EBITDA is 56.40 and 382.1% above the Biotechnology industry median of 11.70. SAB Biotherapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current EV-to-EBITDA is 56.40 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
32GF Score
Get the complete analysis for SABS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
